Redeye concludes that the reported figures mainly were in line with our expectations.
Redeye comments on the outcome of the first step of the capital raise.
Redeye updates its view on Xspray Pharma following an undramatic Q1 2024 report.
Redeye comments on the acquisition announced this morning, where Tobii Dynavox acquires the Australi...
Tar kostnader för åtgärdsplan i kvartalet Omsättningen i kvartalet uppgick till 41,6 mkr, vilket mot...
Lutar åt det positiva Nettoomsättningen utvecklades något svagare än våra förväntningar i Q1(24) och...
G5 reported lower-than-expected topline in Q1, while good cost control supported solid profitability...
Redeye updates on GiG following Q1-results which were lower than expected owing to somewhat softer g...
Redeye initiates coverage of Climeon, providing an attractive waste heat recovery solution generatin...
Containers, dry bulk cargo and the number of passengers grew in Q1 y/y, but liquid bulk cargo contin...
Redeye retains its positive stance towards Hanza despite a softer Q1 report than expected, resulting...
SmartCrafts första kvartal visade på fortsatt bra tillväxt och marginal.
Redeye leave its comments on Xbrane following the announcement of a USD45m deal plus royalties for X...
Tangiamo Touch Technology (”Tangiamo” eller ”Bolaget”) publicerade den 9 maj 2024 bolagets delårsrap...
Administer’s profitability in Q1 improved more than expected, and our 2024E EBITDA estimate is up by...
Etteplan was able to improve its profitability during the first quarter as was expected.
Redeye provides a research update following the Q1 report published by Initiator Pharma earlier toda...
Redeye updates its view of Nanexa following the Q1 report and recent events in the company, includin...
Redeye sees a quarter well in line with our estimates, and we believe that the quarterly reports wil...
Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved r...
